Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Federal Trade Commission
Deloitte
Harvard Business School
Boehringer Ingelheim
Cipla

Generated: March 23, 2019

DrugPatentWatch Database Preview

Ge Healthcare Company Profile

« Back to Dashboard

Summary for Ge Healthcare
International Patents:115
US Patents:7
Tradenames:62
Ingredients:42
NDAs:54
Drug Master File Entries: 5
Patent Litigation for Ge Healthcare: See patent lawsuits for Ge Healthcare

Drugs and US Patents for Ge Healthcare

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare HYPAQUE diatrizoate sodium INJECTABLE;INJECTION 009561-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Ge Healthcare NEPHROFLOW iodohippurate sodium i-123 INJECTABLE;INJECTION 018289-001 Dec 28, 1984 DISCN No No ➤ Sign Up ➤ Sign Up
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 DISCN Yes No 8,916,131 ➤ Sign Up Y ➤ Sign Up
Ge Healthcare OMNIPAQUE 180 iohexol SOLUTION;INJECTION, ORAL, RECTAL 018956-001 Dec 26, 1985 RX Yes Yes ➤ Sign Up ➤ Sign Up
Ge Healthcare OMNIPAQUE 70 iohexol SOLUTION;URETHRAL 018956-007 Jun 1, 1994 DISCN No No ➤ Sign Up ➤ Sign Up
Ge Healthcare ADREVIEW iobenguane sulfate i-123 SOLUTION;INTRAVENOUS 022290-001 Sep 19, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up
Ge Healthcare HYPAQUE SODIUM 20% diatrizoate sodium SOLUTION;URETERAL 009561-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Ge Healthcare

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ge Healthcare VISIPAQUE 320 iodixanol INJECTABLE;INJECTION 020351-002 Mar 22, 1996 4,396,597 ➤ Sign Up
Ge Healthcare OMNIPAQUE 350 iohexol SOLUTION;INJECTION, ORAL 018956-004 Dec 26, 1985 4,250,113 ➤ Sign Up
Ge Healthcare MPI DMSA KIDNEY REAGENT technetium tc-99m succimer kit INJECTABLE;INJECTION 017944-001 May 18, 1982 4,208,398 ➤ Sign Up
Ge Healthcare VISIPAQUE 270 iodixanol INJECTABLE;INJECTION 020351-001 Mar 22, 1996 4,396,597 ➤ Sign Up
Ge Healthcare VISIPAQUE 320 iodixanol INJECTABLE;INJECTION 020351-002 Mar 22, 1996 RE36418 ➤ Sign Up
Ge Healthcare VISIPAQUE 270 iodixanol INJECTABLE;INJECTION 020808-001 Aug 29, 1997 4,278,654 ➤ Sign Up
Ge Healthcare AMIPAQUE metrizamide INJECTABLE;INJECTION 017982-001 Approved Prior to Jan 1, 1982 3,701,771 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Ge Healthcare Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2203431 15C0013 France ➤ Sign Up PRODUCT NAME: DASABUVIR OU UN SEL DE CELUI-CI, NOTAMMENT LE SEL DE SODIUM; REGISTRATION NO/DATE: EU/1/14/983 20150119
0480717 SPC/GB98/025 United Kingdom ➤ Sign Up PRODUCT NAME: MONTELUKAST, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREFERABLY MONTELUKAST SODIUM; REGISTERED: FI 12766 19970825; FI 12767 19970825; UK 00025/0357 19980115; UK 00025/0358 19980115
1611115 2015/004 Ireland ➤ Sign Up PRODUCT NAME: VIZAMYL-FLUTEMETAMOL (18F); REGISTRATION NO/DATE: EU/1/14/941 20140822
1666481 17C1031 France ➤ Sign Up PRODUCT NAME: TOFACITINIB,EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,DONT LE CITRATE DE SODIUM; REGISTRATION NO/DATE: EU/1/17/1178 20170324
1853250 37/2014 Austria ➤ Sign Up PRODUCT NAME: PACLITAXEL, DAS ALS ALBUMIN GEBUNDENE NANOPARTIKEL FORMUIERT IST.; REGISTRATION NO/DATE: EU/1/07/428 (MITTEILUNG) (GEAENDERT DURCH C(2013) 9835) 20131230
0806968 SPC/GB07/011 United Kingdom ➤ Sign Up PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003
0579826 02C0041 France ➤ Sign Up PRODUCT NAME: ERTAPENEM SODIUM; REGISTRATION NO/DATE: EU/1/02/216/001 20020418
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Baxter
Fuji
Moodys
US Department of Justice
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.